Take a look at our sample genetic reports and discover what consumers are learning about themselves and their genetics. Some of our customers could be your patients, and they may want to discuss their reports with you.
View package insert.
Carrier status tests detect genetic variants that can cause inherited conditions. These variants are often found primarily in certain ethnicities.
Being a carrier means your patient has one variant for the condition. Carriers typically don’t have the condition but can pass the variant to their children.
Knowing your patient’s carrier status may be important if he or she is planning a family. If your patient and his or her partner are both carriers, they have a 25% chance to have a child with the condition. If your patient is beyond reproductive age, it may be useful for him or her to share their carrier status results with family members, as they may also be carriers.
Genetic counseling can help your patient understand his or her results and options.
A Genetic Counselor, a health professional with special training in genetic conditions, will be able to answer your patients’ specific questions and help them make informed decisions about testing.
Our carrier status test results* are analytically validated and meet FDA requirements. Specific data on the analytic validity of the variants used in each report can be found on the scientific details page of each report.
Clinical validity is the degree to which a test accurately identifies or predicts a disease of interest. For a variant to be eligible for inclusion in any of the 23andMe carrier status reports, there must be sufficient evidence to establish the pathogenicity defined by:
Prior to inclusion, each variant undergoes review by 23andMe’s scientific and medical teams to ensure that there is sufficient evidence to warrant inclusion.
To ensure that our customers understand the meaning of their 23andMe carrier reports* without relying on a medical professional, we performed rigorous comprehension studies and met all FDA guidelines for consumer comprehension.
Our submission to the FDA for our Bloom Syndrome carrier status test* included a user comprehension study of a group that is representative of the general population of the United States. Results from the user comprehension study revealed that more than 90 percent of participants understood the test instructions and the Bloom Syndrome carrier status* test results.
